Bendrofluazide/Nadolol

苄氟噻嗪/纳多洛尔

Report date: 2022/03/17 10:36:59

Base Information

Drug NameBendrofluazide/Nadolol
Drug Alias NameNadolol/Bendrofluazide苄氟噻嗪/纳多洛尔Bendroflumethiazide/NadololNadolol and BendroflumethiazideCorzide
ClassificationSmall molecules
Mechanisms of ActionThiazide-sensitive sodium-chloride cotransporter inhibitorsImmunostimulantsBeta adrenergic receptors inverse agonists
TargetsThiazide-sensitive sodium-chloride cotransporterBeta adrenergic receptors
Therapy Area/IndicationsHypertension
Global Approved IndicationsHypertension
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date1983/05/25
Country/TerritoryUnited States
CombinationsYes BendrofluazideNadolol
Global Highest StatusWithdrawn
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesKing Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsHypertension

Other Information

ATC CodeC07BA12
Related LinksKEGG